Croton cajucara Benth showed several pharmacological properties such as: anti-inflammatory, antinociceptive hypoglycemic, lipid-lowering, antiulcer, antiestrogenic, antitumor, antigenotoxic, antimutagenic, and cardiovascular. The 19-nor-clerodane diterpene trans-dehydrocrotonin (t-DCTN or DCTN) is the major bioactive constituent extracted from the bark of this Croton. Patents for Croton cajucara Benth in the period 2015 to 2022 comprises 14 published documents. Among them 4 patents are colloidal systems (SM/SNEDDS) loading t-DCTN for pharmacological applications. Patent registrations highlighted the huge promising biotechnological potential of Croton cajucara Benth especially in the phytotherapy field, and the correlation with its bioactive constituents of which t-DCTN showed the foremost results, so this herbal could become an alternative in the treatment of Covid-19. However, investigation of more recently published patents for clerodane diterpenes with similar chemical structure of t-DCTN, who previously showed antiviral property must be carried out and should be searched on several patent data bases.
Keywords: Croton cajucara Benth; Nanotechnology; Nanotechnology advances; New pharmacological perspectives; Patents; Trans-dehydrocrotonin (t-DCNT).
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.